Oncodesign leads consortium for AI-based cancer research

In October, Unicancer Group (Paris, France) joined a consortium led by Oncodesign S.A. (Euronext:ALONC) to develop and apply artificial intelligence technology to identify and characterize patients resistant to cancer therapies. France awarded the four-year project, dubbed OncoSNIPE, a €7.7 million ($9.1 million) grant. The program's total budget is €12 million ($14.2 million).

The consortium will conduct an initial longitudinal clinical trial to research molecular profiles associated with unresponsiveness to treatments in about 600 patients with breast, pancreatic and lung cancer...